Matsuda et al found that Everolimus, a Rapamycin analog, prevented colitis in interleukin-10(IL-10)–/–model by decreasing the percentage of CD4+ T cells in the colonic mucosa and reducing IFN-γ production [24]. Here, CD4 is linked to colitis.